Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under...
Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD...
Barchart Research What to Expect from CMPS Earnings CMPS Generated August 4, 2026 Current Price $11.80 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 10.06% Compass Pathways Between Phase...
Barchart Research What to Expect from CMPS Earnings CMPS Generated July 29, 2026 Current Price $10.90 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 10.06% COMPASS Pathways Reports Before...
Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct...
New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable...